Physician profile
Scott Pethke
NPI 1609828094
$14,240.83
in general payments reported to CMS, 2019-2025
46 companies · $3,139 in 2025
The $3,139 reported for 2025 was more than what 83% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,637 · 2020: $749 · 2021: $1,571 · 2022: $2,488 · 2023: $2,007 · 2024: $2,650 · 2025: $3,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,773 · Education: $22.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,773.32 |
| Education | $22.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,949.32 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $2,945.35 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Actelion Pharmaceuticals US, INC. | $1,496.92 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Genzyme Corporation | $709.82 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $594.02 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $588.73 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Merck Sharp & Dohme LLC | $574.05 | 2019-2025 | Winrevair, Keytruda |
| Insmed, INC. | $565.93 | 2019-2025 | Arikayce |
| Mylan Specialty L.P. | $360.93 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $274.86 | 2024-2025 | Glassia |
| Inspire Medical Systems, INC. | $271.08 | 2022-2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $267.64 | 2019-2025 | |
| Grifols USA, LLC | $265.00 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $238.89 | 2020-2025 | Acthar |
| Shionogi INC | $190.62 | 2022-2024 | Fetroja |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $159.09 | 2022-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Abbvie INC. | $155.93 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $147.63 | 2019-2024 | |
| Amgen INC. | $138.56 | 2022-2024 | Tezspire |
| United Therapeutics Corporation | $129.43 | 2021-2024 | Tyvaso |
| Viatris Specialty LLC | $125.44 | 2025 | Yupelri |
| Ani Pharmaceuticals, INC. | $124.69 | 2023-2025 | Purified Cortrophin Gel |
| Sunovion Pharmaceuticals INC. | $120.26 | 2019-2020 | |
| Avadel Cns Pharmaceuticals, LLC | $91.07 | 2025 | Lumryz |
| Genentech USA, INC. | $91.02 | 2019 | |
| Sanofi-Aventis U.S. LLC | $74.75 | 2022 | |
| Verona Pharma, INC. | $74.74 | 2025 | Ohtuvayre |
| Electromed, INC. | $74.07 | 2023-2025 | Smartvest |
| Pulmonx Corporation | $72.12 | 2020 | |
| Shire North American Group INC | $40.21 | 2019 | |
| Gilead Sciences, INC. | $37.56 | 2019-2025 | Veklury |
| Tactile Systems Technology INC | $33.87 | 2025 | Nimbl, Flexitouch Plus |
| Mallinckrodt Enterprises LLC | $31.67 | 2019 | |
| Inari Medical, INC. | $31.41 | 2021 | |
| Jazz Pharmaceuticals INC. | $23.81 | 2024 | |
| Pfizer INC. | $22.38 | 2025 | |
| Advanced Respiratory, INC | $21.88 | 2021 | |
| Melinta Therapeutics, LLC | $20.44 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.17 | 2021 | |
| Sandoz INC. | $16.82 | 2021 | |
| Philips North America LLC | $15.98 | 2019 | |
| Resmed Corp | $14.60 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $13.50 | 2021 | |
| Eagle Pharmaceuticals, INC. | $12.30 | 2022 | |
| Allergan, INC. | $11.62 | 2019 | |
| Janssen Biotech, INC. | $2.65 | 2024 | Rybrevant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Pethke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.